DARE to PLAY is a topical sildenafil cream enhancing female arousal, available in select states as a compounded product while awaiting FDA approval. Clinical trials showed improved arousal sensation ...

The ProVee System received FDA approval for treating BPH, offering a safe and effective procedure for symptom relief and quality of life improvement. The ProVIDE study showed significant improvement ...

Gepotidacin is now approved for treating uncomplicated urogenital gonorrhea in patients 12 years and older, expanding its previous approval for urinary tract infections. The EAGLE-1 trial showed ...

IsoPSA test analyzes prostate cancer-specific structural variants of PSA protein to aid biopsy decisions in men over 50 with elevated PSA levels. The FDA approved IsoPSA based on a large-scale, ...

In the EMBARK trial in patients with nonmetastatic hormone-sensitive prostate cancer, patients with good PSA responses at 37 weeks had their treatment suspended until their PSA started to rise again.

MRI outperformed micro-ultrasound in sensitivity and negative predictive value for prostate cancer detection. Micro-ultrasound offers a short learning curve and real-time lesion identification, ...

Ibrahim explains the unique challenges men face after spinal cord injury, including neurogenic erectile dysfunction, ejaculatory dysfunction, and particularly the distinctive sperm abnormalities seen ...

FDA clears stapler for use with da Vinci SP surgical system ...

CREST, POTOMAC, KEYNOTE, and ALBAN trials investigate PD-1/PD-L1 inhibitors for BCG-naive bladder cancer patients, focusing on efficacy and safety. Routes of administration vary, with some trials ...

Dr Hamstra describes the three FDA-approved rectal spacers SpaceOAR, Barrigel, and BioProtect, noting differences in placement technique, advantages, potential risks, and the need for long-term ...

Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate cancer. The trial showed consistent benefits across clinical endpoints, ...

Multiple investigational agents have been developed and are being studied. High-risk NMIBC is a resource-intensive entity, with a clinical hallmark being frequent recurrences and risk of progression, ...